AnnAraC | Search

临床试验

计划入组 18 人 · 首次发布于 2010 年 12 月 9 日

已完成

NCT00246636

Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension

计划入组 167 人 · 首次发布于 2005 年 10 月 30 日

已完成

NCT07040345

Annurca Apple Peel Oleolite for the Treatment of Skin Hyperpigmentation

计划入组 48 人 · 首次发布于 2025 年 6 月 27 日

药物

查看全部 5 →

Biotech

Approved

Modified vaccinia ankara(Jynneos)

相关疾病：Ebola Virus Disease, Monkeypox，另有 1 项

MVA-CMDR ankara vaccine(The Rockefeller University)

Wharton's jelly derived mesenchymal stemcells(Ankara Universitesi Teknokent)

机构

查看全部 4 →

Ankara University

Turkey

Ankara Universitesi Teknokent

Turkey

Ankara Bilkent City Hospital

Turkey

资讯

查看全部 22 →

去年

FDA Guidance Enables Moleculin to Streamline Phase 3 Trial for Novel AML Treatment AnnAraC

2年前

Moleculin Advances AML Treatment with Positive FDA Feedback and Plans for Phase 3 MIRACLE Trial

去年

临床试验

Modified Vaccinia Ankara (MVA) Vaccine Study

Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension

Annurca Apple Peel Oleolite for the Treatment of Skin Hyperpigmentation

药物

Modified vaccinia ankara(Jynneos)

MVA-CMDR ankara vaccine(The Rockefeller University)

Wharton's jelly derived mesenchymal stemcells(Ankara Universitesi Teknokent)

机构

Ankara University

Ankara Universitesi Teknokent

Ankara Bilkent City Hospital

资讯

FDA Guidance Enables Moleculin to Streamline Phase 3 Trial for Novel AML Treatment AnnAraC

Moleculin Advances AML Treatment with Positive FDA Feedback and Plans for Phase 3 MIRACLE Trial

Moleculin Biotech Raises $5.9 Million to Advance Annamycin Through Phase 3 AML Trial